Previous 10 | Next 10 |
COMPASS Pathways ADS (CMPS): Q3 GAAP EPS of -$1.30.Cash and equivalents of $196.5M expected to fund operations into 2023.Press Release For further details see: COMPASS Pathways ADS reports Q3 results
London, UK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- · Third quarter and post-period highlights : - Completed upsized initial public offering (IPO) on Nasdaq, raising $146.6 million - Continued to progress phase IIb clinical trial of COMP360 psilocy...
Revive Therapeutics ([[RVVTF]] +1.0%) announces that it has completed an oral thin-film strip product with psilocybin (the active ingredient in "magic mushrooms") in dosage forms between 1 mg and 20 mg. It has also characterized its physio-chemical properties such as tensile strength of the f...
The 2020 election had many areas of significance, with investors focusing on renewable energy, healthcare, and navigating the COVID-19 pandemic effects. But voter approval of one state ballot initiative took a potentially historic step in treatment in mental healthcare. Oregon became th...
London, UK - 9 November 2020 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and ...
The psychedelics story has just begun to gain momentum. We’re already seeing a good deal of clinical studies on psilocybin for example, for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression and anxiety. We’re also ...
London, UK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020 London, UK - 5 November 2020 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to...
How Biotech & Psychedelic Penny Stocks Could See New Bullish Interest in 2021 If you’ve read the title and are wondering what psychedelic stocks are, you’re not alone. This niche area of the stock market has only begun to gain traction in the past few years & ...
Biotech startup Compass Pathways (NASDAQ: CMPS) got good news in the U.S. election last night when Oregon became the first state in the nation to legalize the use of psilocybin -- the active ingredient in psychedelic mushrooms -- as a therapeutic treatment in mental healthcare. ...
London, UK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences London, UK – 4 November 2020 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to ...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...